{"id":89460,"date":"2026-05-16T12:58:57","date_gmt":"2026-05-16T07:28:57","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=89460"},"modified":"2026-05-16T12:58:58","modified_gmt":"2026-05-16T07:28:58","slug":"torrent-pharmaceuticals-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/","title":{"rendered":"Torrent Pharmaceuticals Analyst Review May 2026"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p>This <strong><a href=\"https:\/\/univest.in\/user\/stocks\/torntpharm\/torrent-pharmaceuticals-ltd-share-price-today\">Torrent Pharmaceuticals<\/a> analyst review<\/strong> for May 2026 covers the key data investors need for TORNTPHARM at its current price of Rs 3,400. Torrent Pharmaceuticals (NSE: TORNTPHARM) is a leading pharma company with a market capitalisation of approximately Rs 1,15,000 crore, known for its strong branded generic presence in India, Germany, and the US. The analyst consensus target of Rs 3,900 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether TORNTPHARM achieves that target through FY27.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Torrent_Pharmaceuticals_Company_Snapshot_May_2026\" title=\"Torrent Pharmaceuticals Company Snapshot May 2026\">Torrent Pharmaceuticals Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Analyst_Insight_in_This_Torrent_Pharmaceuticals_Analyst_Review\" title=\"Analyst Insight in This Torrent Pharmaceuticals Analyst Review\">Analyst Insight in This Torrent Pharmaceuticals Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Technical_Analysis_in_This_Torrent_Pharmaceuticals_Analyst_Review\" title=\"Technical Analysis in This Torrent Pharmaceuticals Analyst Review\">Technical Analysis in This Torrent Pharmaceuticals Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Key_Support_and_Resistance_Levels\" title=\"Key Support and Resistance Levels\">Key Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Business_Segment_Analysis\" title=\"Business Segment Analysis\">Business Segment Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#India_Branded_Generics_Chronic_Therapy_Focus\" title=\"India Branded Generics (Chronic Therapy Focus)\">India Branded Generics (Chronic Therapy Focus)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Germany_Heumann_Pharma_and_European_Operations\" title=\"Germany (Heumann Pharma) and European Operations\">Germany (Heumann Pharma) and European Operations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#US_Generics_and_Latin_America\" title=\"US Generics and Latin America\">US Generics and Latin America<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Valuation_in_This_Torrent_Pharmaceuticals_Analyst_Review\" title=\"Valuation in This Torrent Pharmaceuticals Analyst Review\">Valuation in This Torrent Pharmaceuticals Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Trade_Outlook_for_Torrent_Pharmaceuticals\" title=\"Trade Outlook for Torrent Pharmaceuticals\">Trade Outlook for Torrent Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Key_Risks_for_Torrent_Pharmaceuticals_in_FY27\" title=\"Key Risks for Torrent Pharmaceuticals in FY27\">Key Risks for Torrent Pharmaceuticals in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Conclusion_Torrent_Pharmaceuticals_Analyst_Review_Verdict_for_2026\" title=\"Conclusion: Torrent Pharmaceuticals Analyst Review Verdict for 2026\">Conclusion: Torrent Pharmaceuticals Analyst Review Verdict for 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Frequently_Asked_Questions_Torrent_Pharmaceuticals_Analyst_Review_2026\" title=\"Frequently Asked Questions: Torrent Pharmaceuticals Analyst Review 2026\">Frequently Asked Questions: Torrent Pharmaceuticals Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#What_is_the_analyst_target_for_Torrent_Pharmaceuticals_in_2026\" title=\"What is the analyst target for Torrent Pharmaceuticals in 2026?\">What is the analyst target for Torrent Pharmaceuticals in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Is_Torrent_Pharmaceuticals_a_good_investment_at_Rs_3400\" title=\"Is Torrent Pharmaceuticals a good investment at Rs 3,400?\">Is Torrent Pharmaceuticals a good investment at Rs 3,400?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#What_is_Torrent_Pharmaceuticalss_52-week_high_and_low\" title=\"What is Torrent Pharmaceuticals&#8217;s 52-week high and low?\">What is Torrent Pharmaceuticals&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#What_are_the_key_risks_for_Torrent_Pharmaceuticals\" title=\"What are the key risks for Torrent Pharmaceuticals?\">What are the key risks for Torrent Pharmaceuticals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/torrent-pharmaceuticals-analyst-review-2026\/#Where_can_I_get_live_data_and_analyst_targets_for_Torrent_Pharmaceuticals\" title=\"Where can I get live data and analyst targets for Torrent Pharmaceuticals?\">Where can I get live data and analyst targets for Torrent Pharmaceuticals?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Torrent_Pharmaceuticals_Company_Snapshot_May_2026\"><\/span><strong>Torrent Pharmaceuticals Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Torrent&#8217;s India business (55 percent of revenue) grows at 12 to 14 percent YoY in chronic therapy segments (cardiology, CNS, gastroenterology). The Germany business through Heumann Pharma provides European regulatory-quality revenue diversification. The table below summarises the key data referenced in this <strong>Torrent Pharmaceuticals analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>TORNTPHARM<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 3,400<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 3,900<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 2,700<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 1,15,000 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>45.00x<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 3,900<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 4,500<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 2,800<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Insight_in_This_Torrent_Pharmaceuticals_Analyst_Review\"><\/span><strong>Analyst Insight in This Torrent Pharmaceuticals Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Associate Director <strong>Kunal Singla<\/strong> suggests watching Torrent Pharmaceuticals closely in May 2026. At the current market price of Rs 3,400, Kunal Singla flags Pharmaceuticals sector dynamics as a key driver for TORNTPHARM&#8217;s near-term price action. He notes support in the Rs 2,754 to Rs 3,230 zone and flags any sustained close above Rs 3,604 as a positive signal worth tracking. Kunal Singla&#8217;s perspective on Torrent Pharmaceuticals adds a layer of professional technical analysis to this <strong>Torrent Pharmaceuticals analyst review<\/strong> and is not a buy recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_in_This_Torrent_Pharmaceuticals_Analyst_Review\"><\/span><strong>Technical Analysis in This Torrent Pharmaceuticals Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 3,400, TORNTPHARM is trading within its 52-week band of Rs 2,700 to Rs 3,900. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.<\/p>\n<p>Near-term support is identified in the Rs 2,754 to Rs 3,230 band while resistance is seen in the Rs 3,604 to Rs 3,650 zone. A sustained move above Rs 3,604 could open the path toward the analyst consensus of Rs 3,900.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Support_and_Resistance_Levels\"><\/span><strong>Key Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Support Zone:<\/strong> Rs 2,754 to Rs 3,230 &#8211; investors tracking this <strong>Torrent Pharmaceuticals analyst review<\/strong> should watch for a stabilisation or bounce in this range as a potential accumulation signal.<\/li>\n<li><strong>Resistance Zone:<\/strong> Rs 3,604 to Rs 3,650 &#8211; a sustained close above Rs 3,604 would be a positive breakout signal worth flagging.<\/li>\n<li><strong>Medium-Term Target:<\/strong> The analyst consensus of Rs 3,900 represents the base-case upside for this <strong>Torrent Pharmaceuticals analyst review<\/strong>.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Business_Segment_Analysis\"><\/span><strong>Business Segment Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"India_Branded_Generics_Chronic_Therapy_Focus\"><\/span><strong>India Branded Generics (Chronic Therapy Focus)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the primary revenue and margin driver for Torrent Pharmaceuticals, directly supporting the earnings trajectory toward the consensus target of Rs 3,900.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Germany_Heumann_Pharma_and_European_Operations\"><\/span><strong>Germany (Heumann Pharma) and European Operations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This segment adds scale and diversification to Torrent Pharmaceuticals&#8217;s business model and is a meaningful EPS contributor through FY27 and FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"US_Generics_and_Latin_America\"><\/span><strong>US Generics and Latin America<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This represents the medium-term growth frontier for Torrent Pharmaceuticals and a key re-rating catalyst for the stock over the next 12 to 24 months.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_in_This_Torrent_Pharmaceuticals_Analyst_Review\"><\/span><strong>Valuation in This Torrent Pharmaceuticals Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 3,400, Torrent Pharmaceuticals trades at a trailing P\/E of 45.00x. This <strong>Torrent Pharmaceuticals analyst review<\/strong> presents three scenarios: a bull case of Rs 4,500 on strong earnings delivery, a base case of Rs 3,900 at consensus, and a bear case of Rs 2,800 if macro headwinds persist. Q1 FY27 results will be the first key validation point.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<th>Key Condition<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 4,500<\/td>\n<td>Strong earnings and sector tailwinds<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 3,900<\/td>\n<td>Moderate growth, analyst consensus estimate<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 2,800<\/td>\n<td>Earnings miss or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Trade_Outlook_for_Torrent_Pharmaceuticals\"><\/span><strong>Trade Outlook for Torrent Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the technical and fundamental analysis in this <strong>Torrent Pharmaceuticals analyst review<\/strong>, investors might watch TORNTPHARM near the support zone of Rs 2,754 to Rs 3,230 for potential opportunities. A flag above Rs 3,604 could suggest improving momentum toward Rs 3,900. This article uses watch-and-flag language only and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Torrent_Pharmaceuticals_in_FY27\"><\/span><strong>Key Risks for Torrent Pharmaceuticals in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A well-rounded <strong>Torrent Pharmaceuticals analyst review<\/strong> must assess downside risks. Key risks for Torrent Pharmaceuticals include a macro slowdown affecting Pharmaceuticals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in TORNTPHARM.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Torrent_Pharmaceuticals_Analyst_Review_Verdict_for_2026\"><\/span><strong>Conclusion: Torrent Pharmaceuticals Analyst Review Verdict for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Torrent Pharmaceuticals analyst review<\/strong> concludes that at Rs 3,400, TORNTPHARM offers a defined risk-reward with a consensus target of Rs 3,900. The 52-week range of Rs 2,700 to Rs 3,900 provides context on the current entry point. Use this <strong>Torrent Pharmaceuticals analyst review<\/strong> as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on TORNTPHARM.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_Torrent_Pharmaceuticals_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions: Torrent Pharmaceuticals Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Torrent_Pharmaceuticals_in_2026\"><\/span><strong>What is the analyst target for Torrent Pharmaceuticals in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The analyst consensus target is Rs 3,900, with a bull case of Rs 4,500 and a bear case of Rs 2,800. Monitor Q1 FY27 earnings for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Torrent_Pharmaceuticals_a_good_investment_at_Rs_3400\"><\/span><strong>Is Torrent Pharmaceuticals a good investment at Rs 3,400?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 3,400 with a P\/E of 45.00x and a consensus target of Rs 3,900, this <strong>Torrent Pharmaceuticals analyst review<\/strong> is constructive for medium to long-term investors in the Pharmaceuticals sector. Always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Torrent_Pharmaceuticalss_52-week_high_and_low\"><\/span><strong>What is Torrent Pharmaceuticals&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52-week high is Rs 3,900 and the 52-week low is Rs 2,700. At Rs 3,400, TORNTPHARM is positioned within this range as noted in this <strong>Torrent Pharmaceuticals analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Torrent_Pharmaceuticals\"><\/span><strong>What are the key risks for Torrent Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals sector.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_get_live_data_and_analyst_targets_for_Torrent_Pharmaceuticals\"><\/span><strong>Where can I get live data and analyst targets for Torrent Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Torrent Pharmaceuticals&#8217;s live price and analyst targets on the Univest Screener alongside professional financial advice.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Torrent Pharmaceuticals analyst review 2026: CMP Rs 3,400, target Rs 3,900, PE 45.00x. Technical levels, business analysis, and Pharmaceuticals sector outlook.<\/p>\n","protected":false},"author":26,"featured_media":89543,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-89460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778916561:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["83"],"rank_math_focus_keyword":["Torrent Pharmaceuticals Analyst Review"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Torrent Pharmaceuticals Analyst Review 2026: Key Insights"],"rank_math_description":["Torrent Pharmaceuticals analyst review 2026: CMP Rs 3,400, target Rs 3,900, PE 45.00x. Technical levels, business analysis, and Pharmaceuticals sector outlook."],"_thumbnail_id":["89543"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["11794"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/16125829\/Torrent-Pharmaceuticals-Analyst-Review.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/89460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=89460"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/89460\/revisions"}],"predecessor-version":[{"id":89545,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/89460\/revisions\/89545"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/89543"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=89460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=89460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=89460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}